In addition, Escin treatment improved the progression of pulmonary fibrosis in mice, characterized by reduced alveolar structural changes and inflammatory cell infiltration (Figure 8D), inhibition of collagen deposition and α‐SMA+ myofibroblast production in lung tissues (Figure 8E,F; Figure S8I, Supporting Information), as well as the reduction of lung weight to body weight ratio (Figure S8J, Supporting Information). The gene discussed is ACTA1; the disease is pulmonary fibrosis.